Publications by authors named "M Perol"

Claim this Profile
A
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.
S Peters, R Camidge, R Dziadziuszko, S Gadgeel, A T Shaw

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.
Maurice Pérol, Clarisse Audigier-Valette, Hervé Léna, Marie-Ange Massiani, Xavier Quantin

Respir Med Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice.
Christos Chouaid, Philippe Giraud, Marie Wislez, Eric Pichon, Alma Stancu

Respir Med Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Pasi A Jänne, David Planchard, Koichi Goto, Egbert F Smit, Adrianus Johannes de Langen

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.
Caroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, Jean Baptiste Assié, Emmanuel Grolleau

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis